Serotonin and epilepsy

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

In recent years, there has been increasing evidence that serotonergic neurotransmission modulates a wide variety of experimentally induced seizures. Generally, agents that elevate extracellular serotonin (5-HT) levels, such as 5-hydroxytryptophan and serotonin reuptake blockers, inhibit both focal and generalized seizures, although exceptions have been described, too. Conversely, depletion of brain 5-HT lowers the threshold to audiogenically, chemically and electrically evoked convulsions. Furthermore, it has been shown that several anti-epileptic drugs increase endogenous extracellular 5-HT concentration. 5-HT receptors are expressed in almost all networks involved in epilepsies. Currently, the role of at least 5-HT1A, 5-HT2C, 5-HT 3 and 5-HT7 receptor subtypes in epileptogenesis and/or propagation has been described. Mutant mice lacking 5-HT1A or 5-HT2C receptors show increased seizure activity and/or lower threshold. In general, hyperpolarization of glutamatergic neurons by 5-HT 1A receptors and depolarization of GABAergic neurons by 5-HT 2C receptors as well as antagonists of 5-HT3 and 5-HT 7 receptors decrease the excitability in most, but not all, networks involved in epilepsies. Imaging data and analysis of resected tissue of epileptic patients, and studies in animal models all provide evidence that endogenous 5-HT, the activity of its receptors, and pharmaceuticals with serotonin agonist and/or antagonist properties play a significant role in the pathogenesis of epilepsies.

Original languageEnglish
Pages (from-to)857-873
Number of pages17
JournalJournal of Neurochemistry
Volume100
Issue number4
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Epilepsy
Serotonin
Seizures
Receptor, Serotonin, 5-HT2C
Serotonin Antagonists
Serotonin Receptors
Neurons
GABAergic Neurons
5-Hydroxytryptophan
Serotonin Receptor Agonists
Receptor, Serotonin, 5-HT1A
Serotonin 5-HT3 Receptor Antagonists
Depolarization
Synaptic Transmission
Pharmaceutical Preparations
Animal Models
Brain
Animals
Tissue
Imaging techniques

Keywords

  • Animal model
  • Epilepsy
  • GABA
  • Glutamate
  • Selective serotonin reuptake inhibitor antidepressant
  • Serotonin receptor

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Serotonin and epilepsy. / Bagdy, G.; Kecskeméti, V.; Riba, P.; Jakus, R.

In: Journal of Neurochemistry, Vol. 100, No. 4, 02.2007, p. 857-873.

Research output: Contribution to journalArticle

@article{2cc2e99436324361bcdd440cc1ab3a40,
title = "Serotonin and epilepsy",
abstract = "In recent years, there has been increasing evidence that serotonergic neurotransmission modulates a wide variety of experimentally induced seizures. Generally, agents that elevate extracellular serotonin (5-HT) levels, such as 5-hydroxytryptophan and serotonin reuptake blockers, inhibit both focal and generalized seizures, although exceptions have been described, too. Conversely, depletion of brain 5-HT lowers the threshold to audiogenically, chemically and electrically evoked convulsions. Furthermore, it has been shown that several anti-epileptic drugs increase endogenous extracellular 5-HT concentration. 5-HT receptors are expressed in almost all networks involved in epilepsies. Currently, the role of at least 5-HT1A, 5-HT2C, 5-HT 3 and 5-HT7 receptor subtypes in epileptogenesis and/or propagation has been described. Mutant mice lacking 5-HT1A or 5-HT2C receptors show increased seizure activity and/or lower threshold. In general, hyperpolarization of glutamatergic neurons by 5-HT 1A receptors and depolarization of GABAergic neurons by 5-HT 2C receptors as well as antagonists of 5-HT3 and 5-HT 7 receptors decrease the excitability in most, but not all, networks involved in epilepsies. Imaging data and analysis of resected tissue of epileptic patients, and studies in animal models all provide evidence that endogenous 5-HT, the activity of its receptors, and pharmaceuticals with serotonin agonist and/or antagonist properties play a significant role in the pathogenesis of epilepsies.",
keywords = "Animal model, Epilepsy, GABA, Glutamate, Selective serotonin reuptake inhibitor antidepressant, Serotonin receptor",
author = "G. Bagdy and V. Kecskem{\'e}ti and P. Riba and R. Jakus",
year = "2007",
month = "2",
doi = "10.1111/j.1471-4159.2006.04277.x",
language = "English",
volume = "100",
pages = "857--873",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Serotonin and epilepsy

AU - Bagdy, G.

AU - Kecskeméti, V.

AU - Riba, P.

AU - Jakus, R.

PY - 2007/2

Y1 - 2007/2

N2 - In recent years, there has been increasing evidence that serotonergic neurotransmission modulates a wide variety of experimentally induced seizures. Generally, agents that elevate extracellular serotonin (5-HT) levels, such as 5-hydroxytryptophan and serotonin reuptake blockers, inhibit both focal and generalized seizures, although exceptions have been described, too. Conversely, depletion of brain 5-HT lowers the threshold to audiogenically, chemically and electrically evoked convulsions. Furthermore, it has been shown that several anti-epileptic drugs increase endogenous extracellular 5-HT concentration. 5-HT receptors are expressed in almost all networks involved in epilepsies. Currently, the role of at least 5-HT1A, 5-HT2C, 5-HT 3 and 5-HT7 receptor subtypes in epileptogenesis and/or propagation has been described. Mutant mice lacking 5-HT1A or 5-HT2C receptors show increased seizure activity and/or lower threshold. In general, hyperpolarization of glutamatergic neurons by 5-HT 1A receptors and depolarization of GABAergic neurons by 5-HT 2C receptors as well as antagonists of 5-HT3 and 5-HT 7 receptors decrease the excitability in most, but not all, networks involved in epilepsies. Imaging data and analysis of resected tissue of epileptic patients, and studies in animal models all provide evidence that endogenous 5-HT, the activity of its receptors, and pharmaceuticals with serotonin agonist and/or antagonist properties play a significant role in the pathogenesis of epilepsies.

AB - In recent years, there has been increasing evidence that serotonergic neurotransmission modulates a wide variety of experimentally induced seizures. Generally, agents that elevate extracellular serotonin (5-HT) levels, such as 5-hydroxytryptophan and serotonin reuptake blockers, inhibit both focal and generalized seizures, although exceptions have been described, too. Conversely, depletion of brain 5-HT lowers the threshold to audiogenically, chemically and electrically evoked convulsions. Furthermore, it has been shown that several anti-epileptic drugs increase endogenous extracellular 5-HT concentration. 5-HT receptors are expressed in almost all networks involved in epilepsies. Currently, the role of at least 5-HT1A, 5-HT2C, 5-HT 3 and 5-HT7 receptor subtypes in epileptogenesis and/or propagation has been described. Mutant mice lacking 5-HT1A or 5-HT2C receptors show increased seizure activity and/or lower threshold. In general, hyperpolarization of glutamatergic neurons by 5-HT 1A receptors and depolarization of GABAergic neurons by 5-HT 2C receptors as well as antagonists of 5-HT3 and 5-HT 7 receptors decrease the excitability in most, but not all, networks involved in epilepsies. Imaging data and analysis of resected tissue of epileptic patients, and studies in animal models all provide evidence that endogenous 5-HT, the activity of its receptors, and pharmaceuticals with serotonin agonist and/or antagonist properties play a significant role in the pathogenesis of epilepsies.

KW - Animal model

KW - Epilepsy

KW - GABA

KW - Glutamate

KW - Selective serotonin reuptake inhibitor antidepressant

KW - Serotonin receptor

UR - http://www.scopus.com/inward/record.url?scp=33846837628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846837628&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2006.04277.x

DO - 10.1111/j.1471-4159.2006.04277.x

M3 - Article

VL - 100

SP - 857

EP - 873

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 4

ER -